2019 American Society of Hematology Annual Meeting*

Download All
December 7-10, 2019; Orlando, Florida
Review slidesets and analyses of key data from the 2019 Hematology meeting.

Acute and Chronic Leukemias

Capsule Summary Slidesets

Decitabine maintenance showed improved survival outcomes compared with observation alone, especially in FLT3-ITD–negative patients.

Released: December 20, 2019

Retrospective analysis of large cohort of registry patients finds that TDT exerts no significant or clinically relevant effects on outcomes following intensive induction treatment with standard-dose cytarabine/daunorubicin (7+3) in newly diagnosed AML.

Released: December 13, 2019

Combination therapy with FLAG-IDA plus venetoclax is safe and shows activity in newly diagnosed and relapsed/refractory AML.

Released: December 16, 2019

Assessment of first-line hyper-CVAD plus ponatinib in patients with Ph+ ALL demonstrates high response and survival rates and long-term tolerability with adjusted dosing.

Released: December 10, 2019

Venetoclax plus navitoclax (combined with chemotherapy) was well tolerated with promising efficacy in heavily pretreated patients with R/R ALL and LL.

Released: December 9, 2019

Combination enasidenib plus azacitidine improved ORR and CR rates vs azacitidine alone in patients with newly diagnosed AML with IDH2 mutations who were ineligible for intensive chemotherapy.

Released: December 17, 2019

In a retrospective study, older patients with R/R AML following first-line venetoclax plus a hypomethylating agent have poor OS outcomes.

Released: December 13, 2019

High rates of MRD negativity observed in adult patients with Ph+ ALL treated with frontline dasatinib plus blinatumomab.

Released: December 18, 2019

In children and young adults with intermediate- and high-risk first relapse of B-ALL, blinatumomab improved outcomes vs chemotherapy when administered as post-reinduction consolidation therapy prior to transplant.

Released: December 20, 2019

Significant improvement in OS and RFS with CC-486 (oral azacitidine) maintenance therapy in patients with AML in first remission with intensive induction chemotherapy.

Released: December 15, 2019
Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings